Señales en vivo de VECT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 jul 2023 @ 15:59):

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions...

Stats
Volumen de hoy	127 653
Volumen promedio	1.10M
Capitalización de mercado	1.06B
EPS	$0 ( 2023-07-19 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.03
ATR14	$0.430 (2.55%)

Volumen Correlación

Largo: 0.33 (neutral)

Corto: -0.50 (neutral)

Signal:(67.1) Neutral

VectivBio Holding AG Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

VectivBio Holding AG Correlación - Moneda/Commodity

-0.45
( neutral )

0.10
( neutral )

-0.48
( neutral )

0.17
( neutral )

-0.18
( neutral )

0.89
( strong )

VectivBio Holding AG Finanzas

Annual	2022
Ingresos:	$27.34M
Beneficio Bruto:	$27.34M (100.00 %)
EPS:	$-2.12

FY	2022
Ingresos:	$27.34M
Beneficio Bruto:	$27.34M (100.00 %)
EPS:	$-2.12

Financial Reports:

No articles found.

VectivBio Holding AG Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

VectivBio Holding AG

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.